Background: About 1/3 of the total Norwegian population has dyspepsia. The sale of drugs against dyspepsia and Peptic Ulcer Disease (PUD) is increasing.
Objective: To achieve knowledge on use of drugs against dyspepsia and PUD in two urban cohorts. Further to determine factors associated with drug use, and explore whether the use was relevant in relation to dyspeptic symptoms.
Methods: The Oslo Health Study (HUBRO) collected questionnaire data on dyspepsia and PUD symptoms, H. pylori infection and use of drugs against dyspepsia and PUD from about 7000 people aged 40 and 59/60. The H. pylori prevalence was analysed from blood samples, and the impact of infection on symptoms and drug use was examined.
Results: 11,1 % reported symptoms of dyspepsia during the last four weeks. The oldest age group had highest self reported lifetime prevalence of H. pylori (4,9 vs 1,6 %). More men than women reported drug use (13,6 vs 9,1 %). The drug users had higher prevalence of dyspeptic symptoms (46,2 vs 6,7 %). Among the drug users, there was higher prevalence of self reported H. pylori infections (7,8 vs 2,9 %) and more people with PUD (15,8 vs 5,2 %). Antacida were used by 66,2 % of the drug users, while 34,5 % used Histamine H2-antagonists and 34,5 % Proton Pump Inhibitors.
Conclusions: The higher use of drugs among those with symptoms of dyspepsia and PUD indicates relevant drug use. The overall drug use followed Norwegian recommendations.